KRAS and familial pancreatic carcinoma: Accordingly, we tested the effect of sotorasib and adagrasib in combination with both farnesyl-transferase inhibitors (tipifarnib, lonafarnib) on the KRAS-G12C mutant pancreatic cancer cell line MIAPACA2 and a novel patient-derived colorectal cancer cell line PF97.